scholarly journals Impact of blood salvage during liver transplantation on reduction in transfusion requirements

2006 ◽  
Vol 21 (suppl 1) ◽  
pp. 44-47 ◽  
Author(s):  
Ajith Kumar Sankarankutty ◽  
Andreza Correa Teixeira ◽  
Fernanda Fernandes Souza ◽  
Enio David Mente ◽  
Gustavo Ribeiro de Oliveira ◽  
...  

PURPOSE: The aim of this study was to analyse the changes in transfusion requirements, in patients submitted to orthotopic liver transpantation from cadaveric donors, with the use of intraoperative red blood cell salvage (Cell Saver). METHODS: Data from 41 transplants were analysed. Intraoperative blood loss was calculated from the cell salvage, suction and the swabs. The autologous and heterologous transfusions were recorded The red blood salvage was performed using the Cell Saver 5 System (Haemonetics).. For analysis the patients were divided in two groups: one that used the Cell Saver and another that didn't. RESULTS: The median age of the patients was 50 years and the main indication for liver transplantation was cirrhosis (35 cases - 85.3%). The median blood loss was 8362 + 3994 ml (with the Cell Saver) and 10824 + 7002 ml (without the Cell Saver) and the median transfusion of heterologous packed red blood cells was 9,6 + 8 units (with the Cell Saver) compared to 22,3 + 21 units (without the Cell Saver). CONCLUSIONS: The Cells Saver has the potential to reduce the need for heterologous blood transfusion reducing the risks of transmissible diseases.

2017 ◽  
Vol 41 (1) ◽  
pp. 37-42 ◽  
Author(s):  
Hakan K. Atalan ◽  
Bulent Gucyetmez ◽  
Serdar Aslan ◽  
Serafettin Yazar ◽  
Kamil Y. Polat

Purpose: There are many risk factors for postoperative acute kidney injury in liver transplantation. The aim of this study is to investigate the risk factors for postoperative acute kidney injury in living donor liver transplantation recipients. Methods: 220 living donor liver transplantation recipients were retrospectively evaluated in the study. According to the Kidney Disease Improving Global Outcomes Guidelines, acute kidney injury in postoperative day 7 was investigated for all patients. The patient’s demographic data, preoperative and intraoperative parameters, and outcomes were recorded. Results: Acute kidney injury was found in 27 (12.3%) recipients. In recipients with acute kidney injury, female population, model for end-stage liver disease score, norepinephrine requirement, duration of mean arterial pressure less than 60 mmHg, the usage of gelatin and erythrocyte suspension and blood loss were significantly higher than recipients with nonacute kidney injury (for all p<0.05). In multivariate analyses, the likelihood of acute kidney injury on postoperative day 7 were increased 2.8-fold (1.1-7.0), 2.7-fold (1.02-7.3), 3.4-fold (1.2-9.9) and 5.1-fold (1.7-15.0) by postoperative day 7, serum tacrolimus level ≥10.2 ng dL−1, intraoperative blood loss ≥14.5 mL kg−1, the usage of gelatin >5 mL kg−1 and duration of MAP less than 60 mmHg ≥5.5 minutes respectively (for all p<0.05). Conclusions: In living donor liver transplantation recipients, serum tacrolimus levels, intraoperative blood loss, hypotension period and the usage of gelatin may be risk factors for acute kidney injury in the early postoperative period.


2016 ◽  
Vol 40 (12) ◽  
pp. 2988-2998 ◽  
Author(s):  
Sebastian Pratschke ◽  
Alexandra Rauch ◽  
Markus Albertsmeier ◽  
Markus Rentsch ◽  
Michaela Kirschneck ◽  
...  

1996 ◽  
Vol 85 (5) ◽  
pp. 1043-1048 ◽  
Author(s):  
John F. Boylan ◽  
John R. Klinck ◽  
Alan N. Sandler ◽  
Ramiro Arellano ◽  
Paul D. Greig ◽  
...  

Background Patients with end-stage liver disease frequently incur large-volume blood loss during liver transplantation associated with mechanical factors, preexisting coagulopathy, and intraoperative fibrinolysis. Methods Between April 1992 and May 1994, the authors of this double-blind, randomized, placebo-controlled study examined the effect of high-dose tranexamic acid (maximum of 20 g) on blood loss and blood product requirements in patients undergoing primary isolated orthotopic liver transplantation. Primary outcome measures were volume of blood loss (intraoperative blood loss and postoperative drainage) and erythrocyte, plasma, platelet, and cryoprecipitate use during surgery and the first 24 h of intensive care unit stay. Results Patients receiving tranexamic acid (n = 25) had less intraoperative blood loss (median, 4.3 l; interquartile range, 2.5 to 7.9; P = 0.006) compared with the placebo group (n = 20; median, 8 l; interquartile range, 5 to 15.8), and reduced intraoperative plasma, platelet, and cryoprecipitate requirements. Median perioperative erythrocyte use was 9 units (interquantile range, 4 to 14 units) in patients receiving tranexamic acid and 13 units (interquantile range, 7.5 to 31 units) in controls (P = 0.03). Total perioperative donor exposure was 20.5 units (interquantile range, 16 to 41 units) in patients receiving tranexamic acid and 43.5 units (interquantile range, 29.5 to 79 units) in controls (P = 0.003). Results for postoperative wound drainage were similar. Hospital stay and need for retransplantation were comparable in both groups. No patient in either group showed clinical evidence of hepatic artery or portal venous thrombosis within 1 month of transplantation. Conclusions High-dose tranexamic acid significantly reduces intraoperative blood loss and perioperative donor exposure in patients with end-stage parenchymal liver disease who are undergoing orthotopic liver transplantation, with marked reductions in platelet and cryoprecipitate requirements.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 2290-2290
Author(s):  
Marta I Pereira ◽  
Gilberto P Marques ◽  
Carlos Bento

Abstract Abstract 2290 Background: Intra-operative autologous red blood cell (RBC) salvaging (SRBC) reduces requirements for allogeneic RBC transfusion during surgery, and should be considered in surgeries with anticipated blood losses over 1 L. However, the auto-transfusion of large volumes of SRBC can lead to dilutional coagulopathy, due to the loss of clotting factors and platelets during cell processing, worsening the outcome of surgery. Orthotopic liver transplantation (OLT) has historically been associated with major blood loss and massive blood transfusion due to the aggressiveness of surgery, the anhepatic phase and the pre-existing underlying disease. While transfusion requirements have been greatly reduced over the past decade, large volumes correlate with worsened prognosis and can also lead to dilutional coagulopathy. Most published series on cell salvaging focus on orthopedic, cardiac or oncologic patients, and data on its use in liver transplantation remains insufficient and contradictory, with the suggestion that salvage is associated with a higher degree of dilutional coagulopathy than allogeneic transfusion. Methods: We performed a retrospective analysis of a 5-year series of OLT patients undergoing surgery (including for fulminant liver failure) in our Centre, comparing the number of units of Red Cell Concentrate (RCC) transfused during each procedure and the volume of autologous SRBC obtained intra-operatively and reinfused before the conclusion of surgery, with the number of units of fresh frozen plasma (Plasma) and Platelet Concentrate (PC) consumed, as a clinical marker of the depth of coagulopathy, both through univariate and multivariate analysis. Results: A total of 218 OLTs were analyzed; an average of 13.6±17.5 units (U) of RCC, 7.4±12.4 U of Plasma and 5.0±7.9 U of PC were used. In one third of patients (30.7%) no allogeneic RCC was transfused, and in a further third (34.4%) less than 5 U were consumed, resulting in a median of 2 U of RCC per patient. A mean of 1003.4±1061.3 mL of SRBC were reinfused in the 70 patients (32.1%) who underwent salvage. There was no correlation between the number of RCC units and the volume of SRCB infused (−0.04, p=NS), and the mean volume of SRBC was not different between patients who were transfused with RCC (315.3±845.4) and those who were not (337.7±527.0, p=NS); on the other hand, patients who underwent cell salvage used significantly less units of RCC (3.3±6.1) than those who did not (9.4±14.1, p<0.001). We found a strong correlation between the number of Plasma and PC units administered (0.73, p<0.001), and between the number of RCC and Plasma (0.91, p<0.001) and PC units (0.68, p<0.001) used; patients who were transfused with at least 1 U of RCC consumed significantly more Plasma (18.7±18.7 U) and PC (7.1±8.6 U) than patients who did not receive any allo-RCC (1.9±4.0, p<0.001 and 0.3±1.8, p<0.001, respectively). Likewise, there was a significant correlation between the volume of SRBC and the number of Plasma (0.63, p<0.001) and PC units used (0.31, p=0.009); however, patients who underwent cell salvage used significantly less Plasma (7.4±11.7 U) and PC (2.8±6.1 U) than patients who did not (16.1±19.1, p<0,001 and 6.1±8.4, p=0.002, respectively), and patients who received only autologous SRBC were transfused with significantly less Plasma (2.0±4.4 U) and PC (0.0±0.0 U) than patients who received only allogeneic RCC units (20.6±19.8, p<0.001 and 7.6±8.9, p<0.001, respectively). Discussion: The choice to use SRBC was introduced a priori, as reflected in the absence of correlation between the volume of RCC and SRBC used. However, the use of salvaging resulted in a significantly lower need for allogeneic RCC. The volume of allo or auto-RBC needed during surgery correlated with the severity of coagulopathy, and the number of Plasma and PC units administered to revert it were strongly correlated, as expected. However, the choice to use SRBC was associated with a decrease in the volume of Plasma and PC needed, when compared to surgeries without salvaging. Likewise, the exclusive use of SRBC resulted in a significantly lower use of Plasma and PC during surgery than the exclusive use of allo-RCC. Conclusion: In our series, intraoperative salvaging not only reduced the consumption of RCC, but was also associated with a lower severity of surgical coagulopathy, as evaluated clinically through the number of units of Plasma and PC needed to stabilize the patient. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document